2012 News | Events | Industry Updates
Selcia Limited, the international life science contract research organisation, has announced the launch of a new platform to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases ("PPIases").
Simon Saxby, CEO of Selcia Ltd. speaks to EPC about the changes that the pharma industry has faced over the past 12 months and his predictions for 2013.
Selcia Limited, a global leader in 14C radiolabelling and integrated drug discovery service provider, has received GLP re-certification for its analytical laboratory following a successful Good Laboratory Practice (GLP) inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
UK-based Mitopharm Limited, a subsidiary of Selcia Holdings Limited, and Swedish drug development company NeuroVive Pharmaceutical AB have developed three lead drug candidates capable of increasing mitochondrial energy production.
Ongar, UK - 20 Sep 2012. Selcia Limited, the international life sciences contract research organisation, has been granted a UK patent for the technology platform underpinning the company’s CEfrag™ drug screening service.